Belimumab in Lupus Nephritis
Belimumab has been studied in an active lupus nephritis, phase 3 trial call BLISS-LN and shown to be effective as measured by trial of belimumab for the treatment of active lupus nephritis in adult patients.
News
Is Anifrolumab Good Enough for Systemic Lupus Erythematosus?
The NEJM published favorable results of a phase 3 trial of the alpha interferon inhibitor, anifrolumab, showing it to be superior to placebo in active systemic lupus erythematosus (SLE) patients studied for 48 weeks.
Fewer Lupus Flares on Low Dose Steroids
French researchers have shown that patients with systemic lupus erythematosus (SLE) and inactive disease are less likely to flare while taking a 5 mg prednisone maintenance dose.
Obesity Not Discussed by Doctors and Patients
Reuters - Doctors rarely talk about weight concerns with patients who are overweight or obese, and when they do, patients’ experiences tend to be negative, according to a new review of research based on interviews.
A Role for SGLT2 Inhibition in Gout?
The antidiabetic medication canagliflozin (Invokana) lowered serum urate and reduced the risk of gout flare in a post-hoc analysis of data from two large clinical trials.
Domestic Abuse Linked to Fibromyalgia and Chronic Fatigue
Domestic violence was found to predispose to a higher risk of fibromyalgia and those developing chronic fatigue syndrome.
No Cancer Risk with Systemic Necrotizing Vasculitis
The French Vasculitis Study Group has published that patients with systemic necrotizing vasculitis do not have an increased risk of malignancy; in fact they have a risk that is similar to the general population.
Predicting Inpatient Gout Flares
Analysis of New Zealand hospitalized patients revals nine predictors of inpatient flare for people with comorbid gout.
This retrospective cohort study of hospitalised patients with comorbid gout included 625 hospitalised patients, 87 experienced inpatient gout flare.
RheumNow Podcast - The Elusive Hand OA Problem (12.13.19)
Dr. Jack Cush recaps the news and journal reports from the past week on RheumNow.com.
Short-term Benefit with Prednisolone in Hand Osteoarthritis
Lancet reports that prednisolone 10 mg daily for 6 weeks can effectively control the pain of hand osteoarthritis (OA), according to results from the Hand Osteoarthritis Prednisolone Efficacy (HOPE) study. This was a double-blind, randomized, placebo-controlled trial aimed to assess the short-term effects of prednisolone in painful hand OA and synovial inflammation. Patients were required to have hand OA and signs of inflammation in their distal and proximal interphalangeal (DIP/PIP) joints and > 4 DIP/PIP osteoarthritic nodes and at least one DIP/PIP joint with soft swelling/erythema or evidence of synovitis on power Doppler ultrasound. The primary endpoint was finger pain.
CRP in SSc: Identifying a Severe Phenotype
Patients with systemic sclerosis (SSc) who have persistent inflammation -- characterized by consistently elevated levels of C-reactive protein (CRP) -- have more severe disease and worse outcomes, a retrospective study confirmed.
ACR/EULAR Classification Criteria for IgG4 Related Disease
IgG4-related disease (IgG4-RD) is a relatively new disorder since 2003, and may present as a diagnostic challenge as it can cause fibroinflammatory pathology in nearly any organ.
